皮膚エリテマトーデス;
紅斑性狼瘡

Cutaneous lupus erythematosus (CLE) is the skin-related form of lupus erythematosus (LE), with a broad spectrum of clinical manifestations and a variable course. CLE is a frequent finding in patients with systemic lupus erythematosus (SLE) and can also exist as a single entity without associated systemic autoimmunity (LE-specific skin disease). Despite ongoing research into the cause of CLE, it remains unclear how CLE relates to SLE pathogenesis. LE-specific skin disease includes the subtypes of CLE such as acute cutaneous LE (ACLE), subacute cutaneous LE (SCLE), chronic cutaneous LE (CCLE), and intermittent CLE (ICLE). ACLE is characterized by malar rash or maculopapular eruption on sun exposed areas. SCLE characteristically presents as annular or psoriasiform plaques in a photo distribution. CCLE can be further divided into discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain LE (CLE), and LE tumidus (LET). The pathogenesis of CLE is multifactorial and involves genetic predisposition, environmental triggers, and abnormalities in the immune response. It has been reported that many genetic risk factors for CLE involve HLA or interferon-related pathways. Corticosteroids and antimalarials were considered as the most suitable and effective systemic drugs for CLE patients.

免疫系疾患; 皮膚疾患

デキサメタゾン [DR:D00292]
デキサメタゾンリン酸エステルナトリウム [DR:D00975]
ベタメタゾンリン酸エステルナトリウム [DR:D00972]
トリアムシノロンアセトニド [DR:D00983]
ベクロメタゾンプロピオン酸エステル [DR:D00689]
モメタゾンフランカルボン酸エステル [DR:D00690]
ヒドロコルチゾン [DR:D00088]
ヒドロコルチゾンコハク酸エステルナトリウム [DR:D00978]
コルチゾン酢酸エステル [DR:D00973]
トリアムシノロン [DR:D00385]
ベタメタゾン [DR:D00244]
プレドニゾロン [DR:D00472]
プレドニゾロンコハク酸エステルナトリウム [DR:D01239]
メチルプレドニゾロン [DR:D00407]
メチルプレドニゾロン酢酸エステル [DR:D00979]
デキサメタゾンプロピオン酸エステル [DR:D01632]
デキサメタゾン吉草酸エステル [DR:D01948]
酪酸プロピオン酸ヒドロコルチゾン [DR:D01886]
ベタメタゾン吉草酸エステル [DR:D01357]
ベタメタゾンジプロピオン酸エステル [DR:D01637]
ベタメタゾン酪酸エステルプロピオン酸エステル [DR:D02032]
アルクロメタゾンプロピオン酸エステル [DR:D01820]
ジフルコルトロン吉草酸エステル [DR:D01764]
フルドロキシコルチド [DR:D00328]
ジフロラゾン酢酸エステル [DR:D01327]
アムシノニド [DR:D01387]
ジフルプレドナート [DR:D01266]
クロベタゾールプロピオン酸エステル [DR:D01272]
デプロドンプロピオン酸エステル [DR:D01434]
ヒドロキシクロロキン硫酸塩 [DR:D02114]

See also H00080 Systemic lupus erythematosus, and H00291 Familial chilblain lupus (FCL).

PMID:27270345

Stannard JN, Kahlenberg JM

Cutaneous lupus erythematosus: updates on pathogenesis and associations with systemic lupus.

Curr Opin Rheumatol 28:453-9 (2016)
DOI:10.1097/BOR.0000000000000308

PMID:18042093

Kuhn A, Sticherling M, Bonsmann G

Clinical manifestations of cutaneous lupus erythematosus.

J Dtsch Dermatol Ges 5:1124-37 (2007)
DOI:10.1111/j.1610-0387.2007.06554.x

PMID:26850655 (drug)

Chasset F, Arnaud L, Costedoat-Chalumeau N, Zahr N, Bessis D, Frances C

The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): An open-label prospective pilot study.

J Am Acad Dermatol 74:693-699.e3 (2016)
DOI:10.1016/j.jaad.2015.09.064